FY2025 Earnings Estimate for Genmab A/S (NASDAQ:GMAB) Issued By William Blair

Genmab A/S (NASDAQ:GMAB) – Equities researchers at William Blair decreased their FY2025 earnings per share (EPS) estimates for Genmab A/S in a research note issued to investors on Wednesday, April 3rd. William Blair analyst M. Phipps now forecasts that the company will earn $1.07 per share for the year, down from their previous forecast of $1.44. The consensus estimate for Genmab A/S’s current full-year earnings is $1.07 per share. William Blair also issued estimates for Genmab A/S’s FY2026 earnings at $1.60 EPS and FY2027 earnings at $2.16 EPS.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, February 14th. The company reported $0.36 EPS for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The business had revenue of $675.29 million for the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%.

GMAB has been the subject of several other research reports. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday, April 4th. Truist Financial restated a “buy” rating and issued a $50.00 price objective on shares of Genmab A/S in a research note on Tuesday, March 26th. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a report on Tuesday, March 26th. BMO Capital Markets raised Genmab A/S from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $46.00 to $48.00 in a report on Friday, February 23rd. Finally, Citigroup downgraded Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $48.50.

Genmab A/S Stock Up 0.4 %

Shares of GMAB opened at $29.97 on Monday. Genmab A/S has a 52-week low of $26.32 and a 52-week high of $42.99. The stock has a 50 day moving average price of $29.16 and a 200 day moving average price of $30.58. The company has a market capitalization of $19.80 billion, a price-to-earnings ratio of 31.22, a price-to-earnings-growth ratio of 2.12 and a beta of 0.98.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Keybank National Association OH acquired a new position in shares of Genmab A/S in the third quarter valued at approximately $1,154,000. Knights of Columbus Asset Advisors LLC increased its stake in Genmab A/S by 16.8% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 5,712 shares of the company’s stock valued at $201,000 after buying an additional 822 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Genmab A/S by 350.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,845 shares of the company’s stock worth $154,000 after buying an additional 3,770 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Genmab A/S by 83.3% in the 3rd quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock worth $19,717,000 after acquiring an additional 254,042 shares during the period. Finally, HBK Sorce Advisory LLC boosted its holdings in shares of Genmab A/S by 4.8% in the third quarter. HBK Sorce Advisory LLC now owns 9,139 shares of the company’s stock valued at $322,000 after acquiring an additional 419 shares in the last quarter. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.